

ASX Release

Cancelled Options

MELBOURNE, 3 July 2020: Anatara Lifesciences Ltd (ASX:ANR) advises that the following Options have been cancelled:

| Unquoted | Securities – | cancelled: |
|----------|---------------------|------------|
|----------|---------------------|------------|

| ASX Code | Security Description | Number |
|----------|----------------------------------------------------------|---------|
| ANRAE | Options Expiring 14 December 2020 Exercisable at \$1.45 | 202,500 |
| ANRAF | Options Expiring 23 September 2021 Exercisable at \$1.70 | 210,000 |
| | | 412,500 |

Unquoted Securities – on issue following the above cancelled Options:

| ASX Code | Security Description | Number |
|----------|----------------------------------------------------------|-----------|
| ANRAE | Options Expiring 14 December 2020 Exercisable at \$1.45 | 562,500 |
| ANRAF | Options Expiring 23 September 2021 Exercisable at \$1.70 | 210,000 |
| ANRAG | Options Expiring 17 November 2022 Exercisable at \$2.27 | 36,000 |
| ANRAH | Options Expiring 14 December 2020 Exercisable at \$1.45 | 750,000 |
| ANRAI | Options Expiring 17 February 2024 Exercisable at \$0.736 | 600,000 |
| | | 2,158,500 |

STEPHEN DENARO COMPANY SECRETARY

For more information please contact:

| Investor and Media inquiries | | |
|-----------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|--|
| Steven Lydeamore CEO, Anatara Lifesciences Ltd. +61 (0) 438 027 172 slydeamore@anatara.com | Sue MacLeman Chair, Anatara Lifesciences Ltd. +61 (0) 437 211 200 smacleman@anatara.com | |

About Anatara Lifesciences Ltd

Anatara Lifesciences Ltd (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for animal and human health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.